We partner with emerging biotech and biopharma across the full development value chain — clinical development, pharmaceutical (CMC) development, and manufacturing & supply chain, with AI woven through — to build the operational infrastructure serious programs require to scale.
Early-stage biotech teams make decisions about trials, manufacturing partners, suppliers and supply chains — across clinical, CMC and operations — with incomplete information and no dedicated capacity to manage the consequences. Nexaura is the partner that closes that gap across the development value chain — identifying the right partners, processes and contingencies before they become urgent.
Where complexity is the norm, we bring clarity, connection, and the foresight to keep your program moving.
Trial strategy and operations, CRO and vendor selection and oversight, and GCP-aligned quality and regulatory support — so studies run on time and to standard.
CDMO/CMO selection and management, process and analytical development oversight, tech transfer, and CMC strategy for your regulatory milestones.
Supplier selection and qualification, GxP-ready procurement build-out, and supply-chain resilience and second-source strategy.
A proprietary, AI-powered engine screens thousands of manufacturers, CDMOs and suppliers across a continuously enriched, multi-source base — so our sourcing and market maps are grounded in intelligence, not a directory. Two ways to put it to work.
Most of our engagements begin at a specific inflection point — a moment when the cost of a misstep becomes materially higher, and the team does not yet have dedicated operational capacity in place.
Selecting the right CDMO, CMO, or analytical partner before the program's first clinical-grade campaign — when the cost of getting it wrong is measured in months.
Building operational infrastructure to support scale-up and meet investor expectations — without diluting the founding team's focus on the science.
Identifying and mitigating single-source risks, geopolitical dependencies, and material shortages before they become program-threatening events.
Ensuring procurement and supply chain documentation meets GxP and CMC requirements well ahead of the first regulatory conversation.
We are an independent advisory firm with scientific depth, operational experience across the full drug development value chain, and a model built entirely around your outcomes.
Every engagement is led by someone who has built and run these functions inside drug development companies — PhD-level scientific training paired with a decade of supply chain, clinical operations and procurement execution.
We map risks, second sources and operational gaps ahead of the crisis. Our recommendations identify the question behind the question your team is currently asking.
No supplier affiliations. No placement fees. No referral commissions. Our recommendations reflect the best fit for your program — nothing else.
We understand lean teams, high stakes, and the absence of room for costly missteps. Our engagement model scales with your organisation — not the other way around.
Nexaura exists because early-stage teams deserve an operational partner that has actually done the work — across clinical development, CMC and supply chain — not another directory. We bring the infrastructure, partnerships and foresight serious programs need, so your team can stay focused on the science.